Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Adverse Cardiovascular Outcomes in the General Population: Insights From the UK Biobank.

Journal of the American Heart Association·2026

Same author

Soluble Urokinase Plasminogen Activator Receptor Primes Macrophages and Worsens Heart Failure with Preserved Ejection Fraction.

bioRxiv : the preprint server for biology·2026

Same author

Impact of Hypothyroidism on Short-Term and Long-Term Outcomes of Coronary Artery Bypass Graft Surgery.

Thyroid : official journal of the American Thyroid Association·2026

Same author

Soluble urokinase plasminogen activator receptor for risk stratification from undifferentiated acute chest pain through to convalescence after acute coronary syndromes.

European heart journal open·2026

Same author

Perioperative Opioid Use and Risk of Persistent Use After Common Otolaryngologic Procedures.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026

Same author

Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee.

Journal of the American College of Cardiology·2025

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Cardiac natriuretic peptides: from basic discovery to clinical practice.

Salim Hayek¹, Mona Nemer

¹Laboratory of Cardiac Growth and Differentiation, Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Cardiovascular Therapeutics

|May 4, 2010

Summary

Cardiac natriuretic peptides like ANP and BNP are vital for understanding heart failure. Their levels serve as key biomarkers for diagnosis, risk assessment, and guiding therapy, with potential therapeutic applications.

More Related Videos

Isolation of Atrial Myocytes from Adult Mice

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Time-Resolved In Vivo Measurement of Neuropeptide Dynamics by Capacitive Immunoprobe in Porcine Heart

Time-Resolved In Vivo Measurement of Neuropeptide Dynamics by Capacitive Immunoprobe in Porcine Heart

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jun 13, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Isolation of Atrial Myocytes from Adult Mice

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Time-Resolved In Vivo Measurement of Neuropeptide Dynamics by Capacitive Immunoprobe in Porcine Heart

Time-Resolved In Vivo Measurement of Neuropeptide Dynamics by Capacitive Immunoprobe in Porcine Heart

Published on: May 19, 2022

Area of Science:

Cardiology
Molecular Biology
Biochemistry

Background:

Cardiac natriuretic peptides, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), play crucial roles in cardiovascular function.
Dysregulation of these peptides is implicated in various cardiovascular diseases, most notably heart failure.

Purpose of the Study:

To review the function, regulation, and clinical significance of cardiac natriuretic peptides.
To highlight the translation of basic research discoveries into clinical applications for heart failure management.

Main Methods:

Analysis of gene promoters and expression patterns of ANP and BNP.
Review of existing literature on cardiac natriuretic peptides, transcription factors, and clinical trials.

Main Results:

Key regulators and pathways influencing ANP and BNP expression have been identified, including transcription factors like GATA4, TBX5, and NKX2-5.
Plasma natriuretic peptide levels are established biomarkers for heart failure diagnosis, risk stratification, and therapy guidance.
Emerging evidence suggests cardioprotective roles and potential therapeutic uses for natriuretic peptides in myocardial infarction and heart failure.

Conclusions:

Cardiac natriuretic peptides are central to understanding and managing heart failure.
These peptides serve as effective diagnostic and prognostic tools, with ongoing research exploring their therapeutic potential.
The clinical utility of synthetic natriuretic peptides has been demonstrated in trials for heart failure, renal failure, and hypertension.